Genotyping on circulating tumor DNA improves mutation detection rate in high-risk diffuse large B-cell lymphoma  

作　　者：Yi Xia Li Wang Jinhua Liang Haorui Shen Jiazhu Wu Hua Yin Yue Li Huayuan Zhu Jianyong Li Wei Xu 

机构地区：[1]Department of Hematology,The First Affiliated Hospital of Nanjing Medical University,Jiangsu Province Hospital,Nanjing,Jiangsu 210029,China [2]Key Laboratory of Hematology of Nanjing Medical University,Nanjing,Jiangsu 210029,China [3]Collaborative Innovation Center for Cancer Personalized Medicine,Nanjing,Jiangsu 210029,China

出　　处：《Genes & Diseases》2024年第4期116-119,共4页基因与疾病（英文）

基　　金：supported by the National Natural Science Foundation of China(No.81700193,81770166,82170186,81720108002);Jiangsu Province's Medical Elite Programme of China(No.ZDRCA2016022);Project of National Key Clinical Specialty of China,Jiangsu Provincial Special Program of Medical Science of China(No.BE2017751);National Science and Technology Major Project of China(No.2018ZX09734007);China Postdoctoral Science Foundation(No.2021M691336);Jiangsu Postdoctoral Science Foundation of China(No.2021K083A).

摘　　要：Diffuse large B-cell lymphoma(DLBCL)is the most common lymphoma with heterogeneous clinical outcomes.Patients who are primarily refractory to the frontline therapy or relapse less than 12 months after diagnosis have an extremely dismal prognosis.The heterogeneous clinical outcomes of DLBCL patients result from variable genetic profiles.

关 键 词：LYMPHOMA diagnosis clinical 

分 类 号：R733.4[医药卫生—肿瘤]